Eligible patients will be randomized to receive either a single dose of QPI-1002 by IV injection or placebo.
The Phase 3 trial is a double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of QPI-1002 in patients undergoing cardiac surgery. FREMONT, Calif., J(GLOBE NEWSWIRE) - Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced the first patient dosed in the pivotal Phase 3 clinical trial of QPI-1002 a siRNA targeting p53, for the prevention of acute kidney injury (AKI) and its consequences following cardiac surgery (CS) (Trial QRK309, NCT03510897).
0 kommentar(er)
